← Back to Screener
INVO Fertility, Inc. Common Stock (IVF)
Price$2.13
Favorite Metrics
Price vs S&P 500 (26W)-97.31%
Price vs S&P 500 (4W)-45.93%
Market Capitalization$3.57M
All Metrics
Book Value / Share (Quarterly)$43.13
P/TBV (Annual)1.07x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)16.23%
Cash Flow / Share (Quarterly)$-57.28
Price vs S&P 500 (YTD)-44.02%
Gross Margin (TTM)39.17%
Net Profit Margin (TTM)-417.01%
EPS (TTM)$-2092.32
10-Day Avg Trading Volume0.05M
EPS Excl Extra (TTM)$-2092.32
Revenue Growth (5Y)34.57%
EPS (Annual)$-43313.52
ROI (Annual)-32.87%
Gross Margin (Annual)44.00%
Net Profit Margin (5Y Avg)-539.21%
Cash / Share (Quarterly)$2.62
Revenue Growth QoQ (YoY)22.60%
ROA (Last FY)-19.58%
Revenue Growth TTM (YoY)11.50%
EBITD / Share (TTM)$-418.52
ROE (5Y Avg)-241.27%
Operating Margin (TTM)-382.53%
Cash Flow / Share (Annual)$-12146.54
P/B Ratio0.61x
P/B Ratio (Quarterly)0.57x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)0.75x
Net Interest Coverage (TTM)-7.71x
ROA (TTM)-99.55%
EPS Incl Extra (Annual)$-43313.52
Current Ratio (Annual)0.07x
Quick Ratio (Quarterly)0.07x
3-Month Avg Trading Volume0.99M
52-Week Price Return-99.19%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$32.58
P/S Ratio (Annual)0.55x
Asset Turnover (Annual)0.14x
52-Week High$384.00
Operating Margin (5Y Avg)-460.75%
EPS Excl Extra (Annual)$-43313.52
CapEx CAGR (5Y)10.80%
26-Week Price Return-93.32%
Quick Ratio (Annual)0.05x
13-Week Price Return-47.51%
Total Debt / Equity (Annual)0.37x
Current Ratio (Quarterly)0.12x
Enterprise Value$5.195
Revenue / Share Growth (5Y)450.24%
Asset Turnover (TTM)0.24x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)15.11x
Pretax Margin (Annual)-139.60%
Cash / Share (Annual)$2851.54
3-Month Return Std Dev404.48%
Gross Margin (5Y Avg)65.54%
Net Income / Employee (TTM)$-1
ROE (Last FY)-45.02%
Net Interest Coverage (Annual)-29.48x
EPS Basic Excl Extra (Annual)$-43313.52
Receivables Turnover (TTM)26.14x
Total Debt / Equity (Quarterly)0.34x
EPS Incl Extra (TTM)$-2092.32
Receivables Turnover (Annual)41.42x
ROI (TTM)-204.20%
P/S Ratio (TTM)0.51x
Pretax Margin (5Y Avg)-539.09%
Revenue / Share (Annual)$31104.76
Tangible BV / Share (Annual)$8079.00
Price vs S&P 500 (52W)-129.02%
Year-to-Date Return-41.38%
5-Day Price Return9.95%
EPS Normalized (Annual)$-43313.52
ROA (5Y Avg)-93.68%
Net Profit Margin (Annual)-139.25%
Month-to-Date Return-18.75%
EBITD / Share (Annual)$-34056.38
Operating Margin (Annual)-123.57%
LT Debt / Equity (Annual)0.06x
ROI (5Y Avg)-99.68%
LT Debt / Equity (Quarterly)0.16x
EPS Basic Excl Extra (TTM)$-2092.32
P/TBV (Quarterly)0.75x
P/B Ratio (Annual)0.11x
Inventory Turnover (TTM)19.50x
Pretax Margin (TTM)-387.89%
Book Value / Share (Annual)$77709.50
Price vs S&P 500 (13W)-48.19%
Beta2.58x
P/FCF (Annual)2.83x
Revenue / Share (TTM)$80.56
ROE (TTM)-321.75%
52-Week Low$1.92
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
IVFINVO Fertility, Inc. Common Stock | 0.51x | 34.57% | 39.17% | -382.53% | $2.13 |
SYKStryker Corporation | 5.15x | 11.84% | 64.57% | 19.43% | $338.38 |
BSXBoston Scientific Corp. | 4.76x | 15.16% | 69.01% | 18.00% | $63.42 |
MMM3M Company | 3.18x | -4.97% | 39.92% | 18.55% | $150.55 |
MDLNMedline Inc. Class A common stock | 2.21x | — | 26.44% | 7.78% | $46.94 |
BDXBecton, Dickinson and Co. | 2.01x | 6.32% | 46.42% | 12.15% | $154.82 |
RMDResMed Inc. | 6.06x | 11.72% | 60.85% | 33.70% | $224.72 |
DXCMDexCom, Inc. | 5.23x | 19.33% | 62.09% | 19.56% | $61.23 |
WSTWest Pharmaceutical Services, Inc. | 6.22x | 7.44% | 35.91% | 19.03% | $269.81 |
PODDInsulet Corporation | 5.31x | 24.53% | 71.63% | 12.92% | $201.47 |
PENPenumbra, Inc. | 9.31x | 20.16% | 67.14% | 13.48% | $331.47 |
About
INVO Fertility Inc. is a healthcare company focused on expanding access to assisted reproductive technology through its proprietary INVOcell medical device, which enables fertilization and early embryo development to occur within the patient's body. The company operates through three revenue-generating segments: clinical services (including its WFI and Atlanta-based clinics), INVOcell device manufacturing and sales, and therapeutics through its acquired subsidiary NTI. This diversified model combines direct patient care with medical device commercialization to address the growing fertility treatment market.